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Summary 
A skin-associated population of memory T lymphocytes, defined by expression of the cutaneous 
lymphocyte antigen (CLA), binds selectively and avidly to the vascular lectin endothelial cell- 
leukocyte adhesion molecule 1 (ELAM-1), an interaction that may be involved in targeting of 
CLA + T cells to cutaneous sites of chronic inflammation.  Here we present evidence that CLA 
itself is the (or a) lymphocyte homing receptor for ELAM-1. Antigen isolated with anti-CLA 
monoclonal antibody HECA-452 from human tonsillar lysates avidly binds ELAM-1 transfected 
mouse cells. Anti-CLA antibody blocks T lymphocyte binding to ELAM-1 transfectants.  HECA-452 
and ELAM-1 binding to lymphocytes or to isolated tonsillar HECA-452  antigen is abrogated 
by neuraminidase treatment implying a prominent role for sialic acid in CLA structure and function. 
The dominant form of CLA on T cells is immunologically distinct from the major neutrophil 
ELAM-1 ligand, the sialyl Lewis x (sLe  ~) antigen (NeuAcc~2-3GalB1-4[Fuccxl-3]GlcNAc),  which 
is absent, weakly expressed, or masked on T ceUs. However, neuraminidase treatment of CLA + 
T cells, but not of CLA- T cells, reveals Lewis x (CD15) structures.  In combination with the 
known requirement for terminal NeuAcoe2-3Gal  and fucose  residues  attached to N-acetylglucosamine 
for ELAM-1 and HECA-452 binding, this finding suggests that CLA may comprise an additionally 
sialylated or otherwise modified  form of sLe  x.  The identification  of a lymphocyte homing 
receptor for skin may permit novel approaches to the diagnosis and therapy of cutaneous and 
inflammatory disorders. 
M 
ost T cells infiltrating cutaneous sites of inflammation 
express the cutaneous  lymphocyte antigen (CLA) 1 
defined by mAb HECA-452  (1). CLA + T cells represent a 
unique subset of previously activated ("memory") lympho- 
cytes that constitute 10-25%  of circulating  CD3 + PBLs, 
5-10% of T cells in tonsils and peripheral lymph nodes, and 
"~80-90%  of T  cells in  most cutaneous sites of chronic 
inflammation (1,  2).  They are rare in most noncutaneous 
inflammatory sites. The selective localization  of this skin- 
associated memory T cell population  appears to reflect their 
ability to bind to endothelial  cell-leukocyte  adhesion  molecule-1 
1Abbreviations used in this paper: CLA, cutaneous  lymphocyte  antigen; 
ELAM, endothelial cell-leukocyte  adhesion  molectde; HEV, high endothelial 
venules; HSA, human serum albumin; sLe  ~, sialyl Lewis x; WGA, wheat 
germ agarose. 
(ELAM-1) an endothelial ceU lectin of the selectin/LEC-CAM 
family that is preferentially expressed by venules in cutaneous 
sites of chronic inflammation (3). CLA + peripheral blood 
T ceils  bind avidly and almost quantitatively to ELAM-1 trans- 
fected COS cells whereas CLA- T cells bind poorly in com- 
parison. This sdectivity of adhesion raised the possibiLity that 
CLA itself might be involved in or mediate T cell binding 
to ELAM-1. Here we present studies that confirm that CLA 
is a lymphocyte homing receptor for ELAM-1. 
Materials and Methods 
Binding of  ELAM-1 eDNA Transfectants  to Immunoisolated HECA- 
452 Antigen (Ag).  Lymphocyte  CLA is defined by the rat IgM 
mAb HECA-452 (1). Immunoisolated  HECA-452 Ag or control 
glycoproteins  (CD44) were  prepared from tonsil extracts  by mAb 
affinity  chromatography,  employing  a two-step procedure, gener- 
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NP-40-containing lysis buffer and wheat germ agglutinin-binding 
materials were isolated by affinity chromatography on wheat-germ- 
agarose (WGA; Vector, Burlingame, CA) eluting with wash buffer 
containing 0.5 M N-acetylglucosamine. The WGA-binding mate- 
rial was passed through affinity columns of Hermes-1 (rat IgG2a 
anti-human CD44; reference 5), rat IgM mAb control and then 
HECA-452 (rat IgM anti-CLA;  references  1 and 2) coupled to 
Sepharose 4B (Pharmacia, Uppsala, Sweden). Columns were washed 
and eluted with 50 mM ~-octylghcoside-containing wash and acetic 
acid elution buffers. Fractions were collected and neutralized with 
1 M Tris-HC1, pH 8.0. Peak fractions employed in these experi- 
ments contained 0.1-1/~g/ml protein. The purity and composi- 
tion of the tonsillar HECA-452 Ag was as reported by Picker et 
al. (1). For the binding assay, samples of HECA-452 Ag or control 
glycoproteins isolated from tonsil extract were adsorbed onto glass 
wells of 8-chamber Lab-Tek slides (Nunc, Inc., Naperville, IL) by 
dilution in phosphate buffered saline, as previously described for 
the functional reconstitution of the peripheral lymph node addressin 
(4).  After blocking in CM  (5%  normal bovine serum/10 mM 
HEPES, pH 7.0/DMEM; Applied Scientific, San Francisco, CA), 
mouse L1-2 cells transfected with ELAM-1 cDNA, L1-2  ELAM-1, or 
control vector cDNA, L1-2  ..... (6), were applied to each well (1.5 
x  106/0.15 ml CM). After a 25 min incubation at room temper- 
ature on a rotating shaker at 50 rpm, the tops of the wells were 
removed and the slides were washed and fixed in 1.5% glutaralde- 
hyde in  DMEM.  Binding  of ELAM-1  cDNA  transfectants  to 
HECA-452 antigen was similar whether isolated from whole tonsil 
lysates or from tonsil lymphocytes (separated on gradients of Ficoll- 
hypaque; L. Picker, personal observations).  L1-2  EtAM-1 cells did not 
bind control proteins, even when tested at concentrations 10-100- 
fold higher than HECA-452 antigen. In some experiments, glass 
slides coated with HECA-452 Ag or control protein (CD44) were 
incubated with anti-CLA (HECA-452; references I and 2) or con- 
trol rat IgM (RA3-2C2; reference 7) and then washed before assay; 
alternatively,  L1-2  EtAM-1 cells were incubated with anti-ELAM-1 
(CL2; reference 3), anti-human LECAM-1 (Dreg-56; reference 8), 
or anti-mouse T200 (30-G12,  anti-CD45; reference 9) and after 
washing, were applied to HECA-452 Ag or CD44-coated slides. 
For other experiments, HECA-452 Ag and CD44-coated glass slides 
were treated with 5 mU/ml neuraminidase (Vibrio cholera neur- 
aminidase;  Calbiochem, San Diego, CA) in 50 mM sodium ace- 
tate, pH 5.6/100 mM NaC1/10 mM CaC12 with or without 50 
mM sialyllactose (Sigma Chemical Co., St. Louis, MO) or buffer 
alone for 1 h  at room temperature and afterwards were washed 
and blocked with CM before assay. For experiments testing the 
calcium dependence of adhesion, L1-2  ELAM-1 cells were preincu- 
bated in HBSS (without calcium, except where indicated) or HBSS 
with 0.5  mM EGTA for 30 min on ice and  then washed and 
resuspended in either HBSS with 0.5 mM EGTA or HBSS with 
5 mM CaC12. The assay was performed in these buffers on HECA- 
452 Ag or CD44-coated glass slides prepared and blocked as de- 
scribed above. The proportion of L1-2  ELAM-I cells binding was a 
function of the amount of HECA-452 Ag added,  and the extent 
of washing. Under typical conditions (selected to facilitate quanti- 
tation while conserving antigen),  ~200 cells bound per high power 
field, representing 1-2% of input cells. Increasing the percent of 
cells bound had no effect on the results with antibody blocking 
or neuraminidase treatment,  (n  =  1, data not shown). 
Lymphocyte-ELAM-1  Binding Assays.  Normal PBMCs (isolated 
by gradient centrifugation on Ficoll-Hypaque 1077; Sigma Chem- 
ical Co.) were incubated in the presence of anti-LECAM-1 (Dreg- 
56; reference 8), anti-CLA (HECA-452; reference 1, 2), anti-CD45 
(L3B12; reference 10), or control rat IgM (MECAo79;  reference 
11), at 50/zg/ml CM, 2  x  106 cells/ml, 3 ml per plate, on plates 
to which L1-2  ~LAM-1 cells were immobilized. The L1-2  ~tta~-I plates 
were prepared by incubating 3  x  107 cells in 3 ml of CM in 60 
mm plastic plates, previously coated overnight with 10/~g/ml poly- 
t-lysine (Sigma Chemical Co.) for 2 h at room temperature. After 
30-min rotation at 50 rpm, unbound PBMC were removed by two 
washes in HBSS and adherent cells removed by incubation with 
HBSS containing 1 mM EDTA and  1 mM EGTA for 20 min. 
PBMC, which bound the ELAM-1 transfectants, were counted and 
the number of CD3+CLA + cells bound in each experiment was 
calculated by staining an aliquot of the cells and analyzing them 
by FACS  |  analysis. The percent of CLA + T  cells in the PBMC 
preparations  employed ranged from 7-23%. The percent of CLA + 
T cells which bound ELAM-1 transfectants ranged from 11-74% 
in these experiments. Previous studies have shown that essentially 
all CLA + T  cells can be depleted from PBMC by serial incuba- 
tions on ELAM-1 transfected COS cells (3). 
Fluorescence Activated Cell Sorting and Analysis.  For two-color 
FACS  |  analysis, cells were incubated with FITC-conjugated  HECA- 
452 for 30 min, washed in 2.5% normal bovine serum/PBS, then 
incubated with biotin-conjugated anti-CD3 (AMAC, Westbrook, 
ME)  for 30  min.  After washing,  cells were then incubated in 
PE-conjugated streptavidin (Chromaprobe, Mountain View, CA), 
and again washed before analysis. For three-color FACS  |  analysis, 
cells were incubated with anti-CD15  (anti-laY'; AMAC), CSLEX-1 
(anti-sLea; reference 12), or control mouse IgM (MOPC  104E; 
Sigma Chemical Co.) for 20 min, then washed and incubated with 
PE-conjugated goat anti-mouse Ig (Tago Inc., Burlingame, CA) 
in PBS containing 10% normal rat serum, for 20 min. After washing 
again,  cells were incubated in 10% normal mouse serum in PBS, 
then FITC-conjugated HECA-452 and biotin-conjugated anti-CD3 
(AMAC). After a final wash, cells were incubated in streptavidin-PE/ 
allophycocyanin (Southern Biotechnology Associates, Birmingham, 
AL) for 20 min, washed and then fixed with 1% paraformaldehyde/ 
PBS before analysis. FACS  |  analyses were performed on a FACScan  | 
(Becton Dickinson and Co., Mountain View, CA). For experiments 
with separated  CLA + and CLA-  T  cells, HECA-452 + (CLA § 
or HECA-452-  (CLA-) lymphocytes were obtained by staining 
Ficoll-Hypaque-separated PBMC with FITC-conjugated HECA- 
452 (for 20 min at 1 #g/106 cells), washing and sorting positive 
and negative lymphocytes using a FACStar |  (Becton Dickinson 
and Co.). >95% of the lymphocytes in the sorted population were 
HECA-452 §  Neuraminidase  treatment  was  performed by in- 
cubating  cells  at  107/ml  in  PBS  containing  40  mU/ml  Vibrio 
cholera neuraminidase (CalBiochem, San Diego, CA) and 2 mM 
CaCI2 for 40 min at 37~  before staining. Similar results were ob- 
tained using Arthrobacer ureafaciens neuraminidase  or treating cells 
at 4~ 
Results and Discussion 
The lymphocyte CLA antigen is defined by mAb HECA- 
452 (1,  2). To determine whether HECA-452 might define 
functional ELAM-1 natural glycoprotein ligand(s), we used 
affinity isolated tonsillar HECA-452 antigen (HECA-452 Ag) 
as an adhesion substrate for ELAM-1 transfected mouse L1-2 
cells (L1-2EtAM-1). AS shown in Fig.  1, purified HECA-452 
Ag mediates  the binding of L1-2  ELAMq cells, but not con- 
trol transfectants (L1-2'~t~  Control proteins (e.g., H-CAM 
or CD44 isolated from human tonsil) are not adhesive for 
L1-2  ~AM-1 cells (Fig. 2 a-d).  Binding is inhibited by mAbs 
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Figure 1.  Immunoisolated HECA-452 Ag is a ligand for ELAM-1 trans- 
fected cells.  (a) L1-2  ~r^M-t cells and (b) L1-2  ..... cells binding  to HECA- 
452 Ag immunoisolated  from human tonsil lysates and coated onto glass 
slides was as described in Materials and Methods. 
HECA-452  (anti-CLA)  (Fig.  2  a)  and  anti-ELAM-1  (Fig. 
2  b) and is abrogated by treatment  of the antigen  with  neur- 
aminidase  (Fig.  2 c). Adherence of the ELAM-1  transfectants 
is also divalent cation-dependent  (Fig.  2 d). These results dem- 
onstrate  that  HECA-452  recognizes  ELAM-1  binding  spe- 
cies  in  the  tonsillar  lysate.  To confirm  the  participation  of 
CLA  (lymphocyte  HECA-452  Ag)  in  the  specific  binding 
Figure  3.  Binding  of T  lymphocytes  to immobilized L1-2  ELAM-1 cells 
is  blocked  by  anti-CLA.  Normal human PBMCs  (6  x  106) were in- 
cubated on plates containing immobilized L1-2  Erpa~-I cells in the presence 
of the  indicated antibodies.  After  washing,  the bound PBMC  were re- 
moved, counted and analyzed by FACS  |  as described in Materials and 
Methods.  For each  experiment,  replicate plates were  analyzed  and the 
number  of CLA*  T  cells binding is indicated.  Similar results were ob- 
tained when total  CD3 + T  cells were counted (data not shown). 
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Figure 2.  The HECA-452 Ag/ELAM-1 interaction is blocked by anti-ELAM-1 and anti-CLA mAbs, is calcium dependent and neuraminidase sensi- 
tive.  Binding  of L1-2  EtAM-1 cells to HECA-452 Ag immobilized on glass slides, under the various conditions indicated,  was performed as described 
in Materials and Methods.  Data shown are from representative experiments  in which the number  of cells in three to six  100x  fields for each data 
point were counted and standard deviations obtained.  The data were normalized by dividing the number of cells bound by the number of cells binding 
to  HECA-452 Ag in the absence of any pretreatment. 
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Figure 4.  Comparison of the CSLEX1 (anti-sLe  ~) and HECA-452 (anti- 
CLA) reactivity of T cells and neutrophils, a and b are two-color FACS  | 
contour plots of CD3 + T lymphoeytes, and c is a similar plot of nen- 
trophils from the same individual. This representative example shows a 
small snbpopulation of sLe  ~+ T cells, all of which are CLA + (b). Neu- 
trophils stain positively with anti-CLA (HECA-452) and with anti-sLex 
(CSLEX1), and have three-five-fold greater means of sLe  ~ expression than 
the sLe  ~+ T cells (c). Sorted CLA+  T cells (d), but not CLA- T cells 
(e) express CD15 (Le  X) after treatment with neuraminidase. Grey shaded 
plots represent neuraminidase-treated cells, unshaded plots represent cells 
stained before treatment. All lymphocyte plots display only CD3 + T cells, 
selected by light scatter gating and by staining with anti-CD3 in a third 
color. 
of peripheral blood T cells to ELAM-1, antibody inhibition 
studies were also performed. The anti-CLA mAb HECA- 
452, but not control mAbs to LECAM-1, CD45, or isotype 
matched control mAbs, inhibited T cell binding to ELAM-1 
transfectants (Fig.  3). 
The dominant neutrophil ligand for ELAM-1 has recently 
been demonstrated to contain the sialyl Lewis x  (sl.~) an- 
tigen or NeuAxot2-3Galfll-4(Fuco~l-3)GlcNAc (13-15).  SLe  ~ 
is an abundant terminal oligosaccharide of neutrophil N-linked 
glycans in which it occurs linked 81-3 to galactose (16). MAb 
CSLEX1 against sLe  x blocks neutrophil binding to ELAM- 
1 (13, 15); oligosaccharide derivatives of sLeX-fll-3Gal inhibit 
neutrophil binding to ELAM-1 (15); and sLex-fll-3Gal con- 
jugated to human serum albumin binds ELAM-1 transfec- 
rants (6). The lymphocyte ELAM-1 ligand (i.e., CLA) how- 
ever, is believed to be distinct from this neutrophil ligand 
(17,  18). 
Previous studies with mAb FH6 against sLex-i [NeuAcoe2- 
3GalI~1-4(Fuco~1-3)GIcNAc31-3GalI~1-4GlcNAcB1-3-R], 
thought to represent a prominent or dominant form of neu- 
trophil sLe  x] have suggested that sLe  x is not detectably ex- 
pressed by CD3 + T cells (19). Here we used mAb CSLEX1 
(12) to  assess the expression of sLe  x on T  cells.  CSLEX1 
recognizes neutrophil  sLe~-containing oligosaccharides (as 
described above);  binds glycolipids and glycoconjugates of 
the structure sLeX-31-3Gal-R  (6,  12),  and also recognizes 
neuraminidase-sensitive carbohydrate determinants of human 
o+l-acid glycoprotein (T. Yoshino, personal observations) in 
which the fucosylated N-linked glycans contain single lac- 
tosamine units which are linked/3(1-4) to mannose (13, 20). 
Thus, the minimal recognition structure of CSLEX1 appears 
to be the sLe  ~ tetrasaccharide itself. Sensitive flow cytometric 
analysis with peripheral blood cells from 5 different individ- 
uals revealed a small if consistent T cell subset staining with 
CSLEX1.  The mean levels of CSLEX1  reactivity of these 
weakly positive T cells, however, were three- to five-fold less 
than on neutrophils from the same individuals (Fig. 4). Fur- 
thermore, although all of the CSLEX1 § T cells (represent- 
ing  "05%  of CD3 §  T  cells)  were CLA  high,  they con- 
stituted only a fraction (15-30%,  n  =  6) of the CLA + T 
cell population (Fig.  4  b), and both  the CSLEX1 positive 
and negative fractions bind almost quantitatively to ELAM- 
I transfectants (3, and data not shown). These results confirm 
that the predominant ELAM-1 binding structure comprising 
CLA on T cells is immunologically distinct from the major 
neutrophil ligand. 
Recent studies of the reactivity of mAb HECA-452 with 
defined oligosaccharides reveal a strong correlation between 
HECA-452  recognition  and  ELAM-1  binding  (6).  MAb 
HECA-452 recognizes not only CLA but  also neutrophil 
ELAM-1 ligands, including sLe  x.  The HECA-452 antigen 
isolated from myeloid cell lines HL60 or U937 cells, as from 
tonsils,  binds ELAM-1 transfectants, and this binding is in- 
hibited by HECA-452 (data not shown). Furthermore, HECA- 
452 binds sLe~-B1-3Gal conjugated to human serum albumin 
(HSA) (6). Interestingly, HECA-452 also recognizes the isomer 
of sLe  X, the sialyl Lewis a antigen (sLe'), NeuAcc~2-3Gall~l- 
3(Fucoel-4)GlcNAc,  which is a strong ELAM-1 tigand as well 
(6).  Both  HECA-452  and  ELAM-1  transfectants  bound 
sLe~-B1-3Gal-conjugated  HSA at least as avidly as sLe~-31  - 
3Gal-conjugates. Based on computer modeling, these results 
suggested that ELAM-1 and HECA-452 must react with a 
structurally common face of these related carbohydrate struc- 
tures, in which terminal fucose and sialic acid residues are 
presented similarly. Consistent with this, ELAM-1 and HECA- 
452 bound poorly to lacto-N-fucopentaose I, lacto-N-fuco- 
pentaose II (Le~), lacto-N-fucopentaose III (Lex), sialyllacto- 
N-tetraose a and c, implying that the terminal neuraminic 
acid and fucose residues are essential for both antibody and 
lectin recognition (6).  In contrast, CSLEX1 does not bind 
sLe  ~, implying that its reactivity depends on the orientation 
of the GlcNAc (which differs in sLe  ~ and sLe~). As lympho- 
cytes do not express  significant levels of Le  ~ or sLe  * as indi- 
cated by minimal reactivity with anti-sLe ~ or anti-Le  ~ mAbs, 
these findings suggested that, although antigenically distinct 
from neutrophil oligosaccharides bearing sLe  x, CLA might 
be closely related to them. 
Consistent  with  this  hypothesis,  treatment  of  sorted 
CLA § T  cells with neuraminidase unmasks high levels of 
Le  x (CD15) (Fig. 4 d), whereas sorted CLA- T cells remain 
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with  anti-Le  ~ mAbs.  Thus,  although  CLA +  T  cells  bear 
little immunologicaUy detectable sLe  ~, they appear to express 
a sialylated Lewis x structure. Given the structural constraints 
predicted based on ELAM-1 and HECA-452 binding to sLe  ~ 
and sl.~, CLA could comprise disialyl Le  ~, bearing an ad- 
ditional neuraminic acid linked ce2-6 to the core GlcNAc; 
this additional neuraminic acid would not interfere with the 
predicted ELAM-1 binding face of sLe  ~ (6) but would be ex- 
pected to prevent recognition by anti-sLe  ~ mAb CSLEX1. 
Neuraminic acid substitutions have also been reported in ce2-6 
and ce2-8 linkage to galactose, but such modifications would 
be predicted to severely alter the presentation of the essential 
c~2-3-1inked neuraminic acid in relation to the fucose residue 
~J. Magnani, personal communication). Alternatively, CLA 
may bear modified sugar residues preventing recognition by 
anti-sLe  ~ antibodies, or may comprise a more complex (or 
branched) carbohydrate structure. In either case, the presence 
of cryptic CD15  on CLA + lymphocytes but not other T 
cells suggests that their unique ELAM-1 binding ability may 
be conferred in part by expression of an o~(1-3) fucosyl trans- 
ferase, perhaps identical to the myeloid enzyme (21).  This 
fucosyl transferase could operate in conjunction with other 
lymphocyte selective glycosyl transferases (sialyl transferases) 
or other carbohydrate modifying enzymes to generate CLA. 
Our findings are consistent with the proposal that ELAM-1 
on venules in sites of acute inflammation supports neutro- 
phil recruitment, whereas in sites of chronic inflammation 
in  the skin ELAM-1  mediates accumulation of CLA + T 
cells. This situation is remarkably similar to that of the pe- 
ripheral lymph node homing receptor, LECAM-1 (LAM-1 
or bsdectin). LECAM-1 expression on peripheral lymph node- 
homing lymphocytes mediates their interaction with peripheral 
lymph node high endothelial venules (HEV) and is required 
for traflficking through peripheral lymph nodes in vivo (22). 
However, LECAM-1 is highly expressed on neutrophils and 
monocytes, which can bind in vitro to HEV but do not nor- 
really migrate into lymph nodes in vivo (23). These obser- 
vations indicate that selectin-based primary adhesion is not 
sufficient for extravasation and that additional levels of con- 
trol must exist (3, 23).  Indeed we have proposed previously 
that leukocyte extravasation involves an initial, specific but 
reversible, adhesion to endothelium (homing receptor-medi- 
ated), but also requires secondary, integrin-mediated adhe- 
sion step triggered by leukocyte activation (23-26).  Thus, 
both  neutrophils  and  CLA +  T  cells  may interact  with 
ELAM-1 + venules, whether in sites of acute inflammation 
or in chronically inflamed skin, but their subsequent firm 
attachment and extravasation may be regulated by locally pro- 
duced leukocyte-specific activation/chemotactic factors. 
In conclusion, skin-associated memory T cells express the 
cutaneous lymphocyte antigen, CLA, a carbohydrate ligand 
for ELAM-1 which appears to function as a skin lymphocyte 
homing receptor. CLA comprises a sialylated carbohydrate 
structure, probably a sialylated form of I.~ that is closely 
related to, albeit immunologically distinct from, the major 
neutrophil oligosaccharides presenting the sLe  ~ ligand for 
ELAM-1. Interestingly, the carbohydrate epitope defining CLA 
decorates at least one glycoprotein species with molecular mass 
of 200 kD (1). The significance of this protein component 
to T cell binding to ELAM-1 remains to be determined. Im- 
portantly, CLA represents the first homing receptor identified 
that is selective for an extralymphoid tissue rather than an 
organized lymphoid organ. Its expression by a unique subset 
of memory T lymphocytes supports the concept that memory 
T  cells participate in tissue-selective homing pathways that 
martial and segregate immune responses in vivo. 
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